Industry News
Biotechnology Industry News
Vertex Pharmaceuticals is offering…
Vertex Pharmaceuticals is offering Enlaza Therapeutics more than $2 billion in biobucks through a multi-target drug discovery deal aiming to create new T-cell engagers and small-format drug conjugates.
Novartis is taking another shot at…
Novartis is taking another shot at alpha-synuclein as a target for treating Parkinson’s disease via a $200 million upfront licensing deal with Arrowhead Pharmaceuticals.
Merck & Co. has completed a…
Merck & Co. has completed a hat trick of phase 3 victories for its oral PCSK9 inhibitor. Navigating into the broader hyperlipidemia population, the drugmaker stayed out of the shoals and charted a course to
Zymeworks is abandoning a T-cell…
Zymeworks is abandoning a T-cell engager after assessing the cancer drug’s benefit-risk profile in a phase 1 study.
Upstream Bio has sailed to a…
Upstream Bio has sailed to a phase 2 win in sinusitis and plans to push its candidate forward against a competitive current.
As the oral GLP-1 race…
As the oral GLP-1 race intensifies, Eli Lilly has slimmed back the number of phase 2 trials it is conducting for one of its contenders.
AstraZeneca’s hypertension pill…
AstraZeneca’s hypertension pill baxdrostat lowered blood pressure by almost 10 mmHg in a phase 3 trial, the Big Pharma has revealed as it gears up to seek approval.
Roche’s hypertension med…
Roche’s hypertension med zilebesiran may have failed to hit the primary endpoint of the last in a trio of midstage studies, but the Big Pharma has insisted the data were encouraging enough to take the
Roche’s Genentech unit has…
Roche’s Genentech unit has handed over $20 million upfront for the license to Omass Therapeutics’ preclinical inflammatory bowel disease program.
Industry giants Clive Meanwell and…
Industry giants Clive Meanwell and John Maraganore have unveiled a new biotech aiming to disrupt the cardiovascular landscape with a once-annual preventive heart disease candidate and an AI risk-predicting tool.
Zydus Therapeutics has racked up a…
Zydus Therapeutics has racked up a phase 2b/3 win in primary biliary cholangitis, clearing the path to a filing to establish the company as a challenger to Gilead, Intercept Pharmaceuticals and Ipsen.
Fosun Pharma has penned its third…
Fosun Pharma has penned its third inflammatory disease pact in three weeks, plucking up China rights to a clinical-stage treatment from Accro Bioscience.
A phase 1/2 trial of BeOne…
A phase 1/2 trial of BeOne Medicines’ sonrotoclax has hit its primary endpoint, furthering the biotech’s plans to launch the first BCL2 inhibitor for use in mantle cell lymphoma.
Flagship Pioneering is boosting…
Flagship Pioneering is boosting the clinical research capabilities of its biotech fleet with a new IQVIA collaboration. The CRO giant will provide Flagship’s companies with its artificial intelligence and clinical trial technologies to enhance their
The FDA has begun considering a…
The FDA has begun considering a noninvasive liver measurement as a surrogate endpoint for certain MASH patients, a move that could speed up drug development in the space.
Plexium has raised $60.1 million,…
Plexium has raised $60.1 million, providing an infusion of cash to the recently slimmed-down protein degrader specialist three years on from its breakout year.
A phase 1 study has linked…
A phase 1 study has linked Prothena’s anti-amyloid beta antibody to a higher rate of brain swelling than rival approved drugs, hindering the biotech’s positioning in early symptomatic Alzheimer’s disease.
As obesity pioneer Novo Nordisk…
As obesity pioneer Novo Nordisk loses ground in the race for next-generation drugs, the Danish pharma giant is betting on novel RNA technology to bolster its early-stage pipeline. Novo has inked a multiyear research collaboration
Mere months after its cancer…
Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a reorganization that will see the oncology company’s Pennsylvania site wind down and 130 employees laid off,
Amylyx’s withdrawn-from-market…
Amylyx’s withdrawn-from-market Relyvrio has failed to make an impact on primary or secondary endpoints in a rare neurodegenerative disease, prompting the company to discontinue the program.